 Mustang Bio remains underfollowed despite having several therapies that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases. MBIOs share price is near the 52-week lows despite the company completing milestones and a few bullish catalysts ahead. Several programs are moving closer to their pivotal studies. 